Biopharma executives and outside counsel honed in on several issues that could impact the way companies promote their medical products at the Food and Drug Law Institute’s advertising and promotion conference last month. Below are some activities they worry could be the subject of enforcement action, as well as a court ruling that could restrict biosimilar promotion.
One panel was devoted to the risks that drug and device manufacturers face with their use of hubs that assist...